MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration
Профиль экспрессии микроРНК позволяет дифференцировать доброкачественные узлы от папиллярных карцином щитовидной железы по клеткам, полученным при тонкоигольной аспирации
2012-06-24
SCID: 54.1/et8wcvh2
Discuss with AI
BRAF V600E mutationfine-needle aspirationmicroRNA expression profilingpapillary thyroid carcinomaquantitative RT-PCR
Figures from the paper
Abstract (AI)
OBJECTIVE: MicroRNAs (miRNAs) are small endogenous noncoding RNAs that pair with target messengers regulating gene expression. Changes in miRNA levels occur in thyroid cancer. Fine-needle aspiration (FNA) with cytological evaluation is the most reliable tool for malignancy prediction in thyroid nodules, but cytological diagnosis remains undetermined for 20% of nodules. DESIGN: In this study, we evaluated the expression of seven miRNAs in benign nodules, papillary thyroid carcinomas (PTCs), and undetermined nodules at FNA. METHODS: The prospective study included 141 samples obtained by FNA of thyroid nodules from 138 patients. miRNA expression was evaluated by quantitative RT-PCR and statistical analysis of data was performed. Genetic analysis of codon 600 of BRAF gene was also performed. RESULTS: Using data mining techniques, we obtained a criterion to classify a nodule as benign or malignant on the basis of miRNA expression. The decision model based on the expression of miR-146b, miR-155, and miR-221 was valid for 86/88 nodules with determined cytology (97.73%), and adopting cross-validation techniques we obtained a reliability of 78.41%. The prediction was valid for 31/53 undetermined nodules with 16 false-positive and six false-negative predictions. The mutated form V600E of BRAF gene was demonstrated in 19/43 PTCs and in 1/53 undetermined nodules. CONCLUSIONS: The expression profiles of three miRNAs allowed us to distinguish benign from PTC starting from FNA. When the assay was applied to discriminate thyroid nodules with undetermined cytology, a low sensitivity and specificity despite the low number of false-negative predictions was obtained, limiting the practical interest of the method.
Key Findings
1
A three-miRNA model using miR-146b, miR-155, and miR-221 distinguished benign nodules from papillary thyroid carcinomas using fine-needle aspiration samples.
2
Application to 53 cytologically undetermined nodules produced 31 valid predictions, with 16 false positives and six false negatives.
3
BRAF V600E was detected in 19 of 43 papillary thyroid carcinomas and one of 53 undetermined nodules; limited sensitivity and specificity reduced the method’s practical utility for indeterminate nodules.
4
Cross-validation estimated the reliability of the miRNA classification model at 78.41%.
5
The miRNA-based decision model correctly classified 86 of 88 nodules with determined cytology, corresponding to 97.73% validity.
Research Object
Thyroid nodules, including benign nodules, papillary thyroid carcinomas, and nodules with undetermined cytology, sampled by fine-needle aspiration
Research Subject
MicroRNA expression profiles—particularly miR-146b, miR-155, and miR-221—as markers for distinguishing benign nodules from papillary thyroid carcinomas and classifying cytologically undetermined nodules
Publication Details
Publication Date
2012-06-24
Journal
Publisher
ISSN
Cited by
70
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest